A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease (NCT07577843)
A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).
Who can join: Review the eligibility criteria below.
Location: Clinnova Research — Anaheim, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (142 Sites)
Showing the first 25 of 142 sites.
- Clinnova Research — Anaheim, California
- Gastro SB Clinic — Chula Vista, California
- United Medical Doctors — Los Alamitos, California
- Medical Associates Research Group, Inc. — San Diego, California
- Peak Gastroenterology Associates — Colorado Springs, Colorado
- Florida Research Center Inc. — Lakewood Rch, Florida
- Sanchez Clinical Research, Inc — Miami, Florida
- GCP Clinical Research — Tampa, Florida
- Atlanta Gastroenterology Specialists — Suwanee, Georgia
- Tri-State Gastroenterology Assoc — Crestview Hills, Kentucky
- Gastroenterology Clinic of Acadiana — Lafayette, Louisiana
- Michigan Center of Medical Research — Farmington Hills, Michigan
- New York Gastroenterology Associates — New York, New York
- University of North Carolina Hospital — Chapel Hill, North Carolina
- Great Lakes Gastroenterology Research, LLC — Mentor, Ohio
- Digestive Disease Specialists Inc — Oklahoma City, Oklahoma
- The Oregon Clinic — Portland, Oregon
- Gastro One — Cordova, Tennessee
- Tyler Research Institute, LLC — Tyler, Texas
- GI Alliance Tacoma — Tacoma, Washington
- GEDYT — AAI,
- Globalpsy — La Plata,
- HIGEA — Mendoza,
- Cer Instituto Medico — Quilmes,
- Banksia Trials SA — Adelaide,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohn Disease
- Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease — Lutherville, Maryland
- Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial — New Haven, Connecticut
- A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease — Portland, Oregon
- Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) — Ottawa, Ontario
- A Long-term Extension Study of Ustekinumab in Pediatric Participants — Atlanta, Georgia
- Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease — Atlanta, Georgia
Explore by condition: All Crohn Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.